Source BioSciences Half Year Report for the Six Months Ended 30 June 2012
Published: Aug 21, 2012
The Group is delighted to announce that Mr Robert Bakewell, Finance Director, will join the Board with immediate effect. Rob joined Source BioScience in 2005 and has been Finance Director of the Group, in a non-board capacity, since 2011. Rob converted the Group to IFRS and has overseen the consolidation of the finance function and associated systems as the Group has expanded. Rob qualified as a Chartered Management Accountant in 1996 and has over ten years of regulatory compliance and corporate activity experience for listed companies. Prior to joining the Group he was Financial Controller at DCS Group plc, which provided software solutions to global freight organisations and European motor retailers from subsidiaries in Europe and the USA.
After more than eight years of service as a Non Executive Director, Robin Slinger believes that it is now appropriate to step down from the Board. Since joining the Group in 2004, Robin has provided guidance and independent appraisal across the full spectrum of business matters and disciplines. Everyone at Source BioScience would like to thank Robin for his diligence, and input, and wish him all the best in his future endeavours.
Laurie Turnbull, Chairman, said: “I am very pleased to welcome Rob to the Board. His appointment will strengthen the range of financial and regulatory expertise available to the Board as it continues with the implementation of the Group’s growth strategy.”
There is no additional information required to be disclosed pursuant to paragraph 9.6.13 of the Listing Rules.
For further information, please contact:
Source BioScience plc
Dr Nick Ash, CEO
Tel: +44 (0)115 973 9010
College Hill (PR Agency to Source BioScience)
Melanie Toyne-Sewell/Jayne Crook
Tel: +44 (0)20 7457 2020
About Source BioScience:
Source BioScience plc (LSE: SBS) is an international diagnostics and genetic analysis business serving the healthcare and research markets. The LifeSciences division provides core laboratory research support from conceptualisation to implementation, calling upon a wide range of cutting-edge technology platforms including an online catalogue of biomolecular tools. The Company is a trusted provider of a complete range of sophisticated microarray, next generation and conventional sequencing services. GLP, GCP and CPA accreditations make the sequencing offerings also very attractive for applications in regulatory studies or clinical settings. Its Healthcare operations provide screening and reference laboratory diagnostic testing for cancer and other diseases and additional predictive testing for treatment optimisation for clinicians and patients. The Group has its headquarters in Nottingham, UK. Further information about Source BioScience can be found at www.sourcebioscience.com